DermNaPort
The new Nano-Lipid-Vehicle
To bring Pharmacia, Extracts and
Essential oils in high concentration in
and through the skin.
Monterrey, Mexico 2007
A new and effective topic procedure
for the localised treatment of local illnesses
using proven ingredients
without systemic side effects
Applying Nano-Technology
SKINCONNECTIVE TISSUE
Joints, Tendons
• Acné• Herpes Zoster• Neurodermitis• Healing/regeneration• Couperosis• Spider Naevi• Hemangioma• Skin pigmentation• Stretch marks• Cellulitis• Wrinkles• Tromboflebitis• Mycosis• Alopecy• Bags under the eye• Post-Zoster neuralgy
• Rheumatic Arthrtis
• Osteoarthritis
• Chronic Poliarthritis
• Gout
• Tendopathy
• (CRPS)
• Knee
• Hand
• Hips
• Foot
APPLICATION OPORTUNITIES FOR OUR DERMNAPORT SYSTEM
DermNaPortSystem
Nº of micelles (n) = 1,9 x 1018
d 10 Nanometer
Phase surface
= n d² = 1,9 1018 3,14 10-16 = 600 m²
Nano emulsions have specialy large phase surfaces
HOW DOES OUR NANOTECHNOLOGY WORK?
1 cm
HOW DOES OUR NANO-LIPID-VEHICLE WORK?
Due to spetialy large phase surface nano emulsions can absorb largequantities of active ingredients.Nano emulsions, together with active ingredients, can deeply penetrate the skin.
skin
Without Nano-technology With Nano-technology
skin
Due to the characteristics of this nano technology, our state of the art vehicleallows for a very effective transdermal transport of virtually any product onthe market
Effectiveness of actual commercial products is very limited(lotions, gels, crémes, sprays, etc.)
COMPARISON
Nano-Gel(Home
application)
Liquid(for clinical use)
DermNaPort
3 CUTANEOUS PENETRATION ALTERNATIVES
Inter-cellular
Trans-cellular
Trans-glandular
transfolicular
Besides the inter-cellular method, other penetration options do exist:
The transfolicular option is for veterinary medicine of great importance.
These Nano-preparations allow for effective topic therapy with highly effective active ingredients for local illnesses.
Such active ingredients have a very high toxicity index when taken systemicaly:
DERMNAPORT PRINCIPLE
traditional DermNaPort
System
Oral intake
Systemic:• Reduced concentration on local problem• limited effectiveness• Damages to the body
Tópic:• High concentration on local problem• Maximum effectiveness• No damages to the body
Toxicity index Local application
TYPES OF ADMINISTRATION
DermNaPortSYSTEM
Clinical administration: Home administration
General Presentation: Nano-Gel
- Lower concentrations- Easy & safe administration- For post-treatment use- Without side effects
Presentation: Liquid
- Constant medical supervision - High concentrations- More effective- Individual dosage- Precise dosage- Máximum skin penetration- Without side effects
PROBLEM:
PAIN
• In the previously mentioned cases, pain is an
essential factor
• Overall, pain is a problem that cuts deep into
society and its functional and intrapersonal
relationships.
SITUATION IN MEXICO
• 10% of the population suffers from reumatic illness.
• 50% of the working population do suffer at least one back pain episode per year.
• 80% of the population suffer of an acute back pain during their livespan.
• 3 millions suffer from osteroarthritis.
• 10 millions have degenerative arthritis.
• 30 millions take pain medication.
RESULTS
WHO CAN BENEFIT FROM OUR SYSTEM?
CRPSJoint degeneration
TendinopatiaLumbalgia
GoutPolineurpathy
RheumatismArthritis & Poliartritis
Patients who suffer:
SUCCESS RATES (PER BODY AREA)
Overall success rate: 80% Total number of treatments: 147 Average number of treatments: 7
Neck: 80%Nº. T.: 11Nº.D.: 75
Shoulder/ Hands 85%Nº.T.: 77Nº.D.:359
Ellbow/ Hands: 100 %Nº.T.: 31Nº.D.: 96
Thigh: 75 %Nº.T.: 3Nº.D.: 8
Knee: 100 %Nº.T.: 20Nº.D.: 59
Tests were made on 20 cases in German pain managment centers which have undergoneprevious unsuccessfull treatments
SUCCESS RATES PER SKIN AND JOINT CONDITION
General succes rate: 74% (on previously unsuccessful treated patients)
CONCLUSIONS
High efficiency rate (aprox. 80%)
Altos niveles de efectividad
Only administered localy
Use of injections not neccesary
No secondary toxic effects
Does not react when mixed with other medication
Can be safely administered on polimorbide patients
Easy administration
It is a universal vehicle for topic administration
Does not irritate the skin
BIBLIOGRAFÍA
Prof. Dr. Med. LotzTenure track Professor at the University of Ulm in the medicine field. Medical specialist in anesthesia and pain management. Director of pain management center in Bad Liebesspringe (DE)
Dr. Med. SteinbergPATerapeuta para el dolor. Private medicine sector. Medical specialist in pain management.
Today in Mexico we do have done more then 100 succesfull new cases.
THANK YOU VERY MUCH
FOR YOUR ATTENTION
Wherever possible our innovations and
developments are beeing protecded by
national and international patents and
patents applications
Top Related